CTLA4 and metastatic melanoma: In March 2011, the U.S. Food and Drug Administration (FDA) approved ipilimumab, a cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor, as the first immune checkpoint inhibitor (ICI) for treating metastatic melanoma[4].